S-3 GROUP

Lobbying for ALKERMES, INC. · Global biopharmaceutical company specializing in innovative treatments

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · District of Columbia · House · Senate · $90,000.00 income · posted Jan 16, 2026

Lobbying activity 1

Alcohol and Drug Abuse

Issues related to legislation and policies that support treatment for alcohol and opioid dependency at SAMSHA, VA and DOJ

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.